arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

IMMUCELL CORP /DE/

ICCC
$9.94 ▼ -0.37 (-3.54%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
68 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
41
Health
Weak
Bearish
auto_awesome

Analytical Summary

IMMUCELL CORP /DE/ faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $90.1M
Dividend Yield —
Revenue Growth 11.5% ↘
Op. Margin 26.9% ↗
ROIC 4.8% ↘
FCF / Share $0.25 ↘
Trailing P/E 49.7x
Price / Book 2.9x
FCF Yield 2.5%
Debt / Equity 0.26
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.19M
↑ +11.5% —
Net Income Profit after all expenses
$1.83M
↑ +265.6% —
Operating Margin Operating profit as % of sales
26.9%
↑ +41.6% 46th
FCF / Share Free cash flow per share
$0.25
↓ -32.8% —
Long-Term Debt Long-term obligations
$8.30M
↓ -4.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability →
37
Returns ↓
39
Financial Health ↑
65
Cash Quality
9

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters